Hyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD) Clinical Trial
Official title:
Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network
| Verified date | September 2018 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This is a cross-sectional retrospective study of laboratory records of patients who take electrolytes blood tests containing the data of the serum potassium level. This study is an observational one, and there is no intervention into routine clinical practice either in terms of therapy, or special examinations.
| Status | Completed |
| Enrollment | 53940 |
| Est. completion date | September 15, 2017 |
| Est. primary completion date | September 15, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Males and females tested in the Russian centres of INVITRO laboratory from 01.01.2015 till 31.12.2016; - 18 years and older; - Available electrolytes blood test containing of the serum potassium level of the unique patient fits for interpretation. Exclusion Criteria: - Blood test cannot be interpreted due to various reasons. - Blood samples with sing of hemolysis |
| Country | Name | City | State |
|---|---|---|---|
| Russian Federation | Invitro | Moscow |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Russian Federation,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | the proportion of the individuals with the serum potassium level higher than 5.0, 5.5, and 6.0 mmol/L | To determine the proportion of the individuals with the serum potassium level higher than 5.0, 5.5, and 6.0 mmol/L based on INVITRO laboratory database during 2015-2016 years. | One day |